Figure 1: Western blot analysis using Vimentin mouse mAb against Hela (1), COS (2), HEK293 (3) and U20S (4) cell lysate.
Mouse Monoclonal Antibody to Vimentin

Mouse Monoclonal Antibody to Vimentin

20301

Regular price $352.00 $299.00 You Pay

Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: Vimentin, also know as VIM. It is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets. Vimentin phosphorylation by a protein kinase causes the breakdown of intermediate filaments and activation of an ATP and myosin light chain dependent contractile event. This results in cytoskeletal changes that facilitate the interaction of the lipid droplets within mitochondria, and subsequent transport of cholesterol to the organelles leading to an increase in steroid synthesis. Immunohistochemical staining for Vimentin is characteristic of sarcomas (of neural, muscle and fibroblast origin) compared to carcinomas which are generally negative. Melanomas, lymphomas and vascular tumors may all stain for Vimentin. Vimentin antibodies are thus of value in the differential diagnosis of undifferentiated neoplasms and malignant tumors. They are generally used with a panel of other antibodies including those recognising cytokeratins, lymphoid markers, S100, desmin and neurofilaments.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000
Size: 100 ul, 1mg/ml
Species Reactivity: Human; Monkey
Clone: 4F2E9;
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of Vimentin (aa2-466) expressed in E. Coli. ;
Formulation: Ascitic fluid containing 0.03% sodium azide. ;
MW: 54kDa
Storage: 4C; -20C for long term storage
Spplier link: http://www.promab.com/index.php?main_page=product_info&products_id=290
Reference: 1. Cancer Res. 2003 May 15;63(10):2658-64. ; 2. Exp Cell Res. 2007 Oct 15;313(17):3718-28.